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1. INTRODUCTION {#cam42808-sec-0005}
===============

Oral squamous cell carcinoma (OSCC) is the sixth most prevalent malignancy in the world,[1](#cam42808-bib-0001){ref-type="ref"} and often occurs in the lips, tongue, buccal mucosa, floor, gingiva, hard palate, and retromolar trigone.[2](#cam42808-bib-0002){ref-type="ref"} A study indicates that young white population aged 18‐44 years have a higher rate of developing OSCC.[3](#cam42808-bib-0003){ref-type="ref"} Though efforts have been made in advancing the diagnosis and treatment methods, 5‐year survival rate of patients with OSCC is still not satisfactory.[4](#cam42808-bib-0004){ref-type="ref"} Therefore, OSCC treatments, including extending survival time, remain a challenge to be solved.

Long noncoding RNAs (lncRNAs) can form complex networks by the interactions with microRNAs (miRNAs), messenger RNAs (mRNAs), and proteins, and play pivotal roles in different cancers.[5](#cam42808-bib-0005){ref-type="ref"} LncRNAs are involved in the progress of OSCC through affecting various aspects of cellular homeostasis.[6](#cam42808-bib-0006){ref-type="ref"} LncRNA urothelial cancer‐associated 1 (*UCA1*) exerts critical effects on various cancers. LncRNA *UCA1* is elevated in the bile duct carcinoma (BDC) and promotes BDC cell migration and invasiveness.[7](#cam42808-bib-0007){ref-type="ref"} Moreover, lncRNA *UCA1* can promote human pancreatic ductal adenocarcinoma stem cell properties and suppress tumor growth.[8](#cam42808-bib-0008){ref-type="ref"} The oncogenic role of lncRNA *UCA1* in other cancers, including glioblastoma,[9](#cam42808-bib-0009){ref-type="ref"} bladder,[10](#cam42808-bib-0010){ref-type="ref"} gastric,[11](#cam42808-bib-0011){ref-type="ref"} and prostate cancer,[12](#cam42808-bib-0012){ref-type="ref"} has been reported, the function of *UCA1* in OSCC remains to be elucidated.

MiRNAs can also function vitally in the posttranscriptional regulation through binding to the 3'UTR of mRNAs. It is revealed that miRNAs can be separated by lncRNAs from their target mRNAs.[13](#cam42808-bib-0013){ref-type="ref"} MiR‐143‐3p shows a tumor‐suppressive role in many cancers such as cervical cancer,[14](#cam42808-bib-0014){ref-type="ref"} osteosarcoma,[15](#cam42808-bib-0015){ref-type="ref"} colorectal cancer,[16](#cam42808-bib-0016){ref-type="ref"} and laryngeal squamous cell carcinoma [17](#cam42808-bib-0017){ref-type="ref"}; however, whether miR‐143‐3p has a tumor‐suppressive function in OSCC remains unclear.

Myosin VI (*MYO6*), which is widely expressed in various organisms and tissues, is a unique member of the myosin superfamily.[18](#cam42808-bib-0018){ref-type="ref"} *MYO6* could serve as an oncogene in human cancers, for instance, knocking down *MYO6* suppresses the growth and induces the apoptosis in prostate cancer, colorectal cancer, and gastric cancer.[19](#cam42808-bib-0019){ref-type="ref"}, [20](#cam42808-bib-0020){ref-type="ref"}, [21](#cam42808-bib-0021){ref-type="ref"} In addition, knockdown of *MYO6* also inhibits the proliferation of OSCC cells.[22](#cam42808-bib-0022){ref-type="ref"} Although *MYO6* has been reported in many human tumors, including OSCC cells, its role in OSCC is unknown.

In the current study, we explore the clinical characteristics and role of lncRNA *UCA1* in OSCC. We demonstrated that *UCA1* was markedly increased in OSCC tissues and cells, and that *UCA1* facilitated the progression of OSCC via regulating the miR‐143‐3p/MYO6 axis.

2. MATERIALS AND METHODS {#cam42808-sec-0006}
========================

2.1. Clinical tissues and cell lines {#cam42808-sec-0007}
------------------------------------

The tissues and matched adjacent normal tissues were collected from 56 OSCC patients (males/females, aged between 32 and 24 years, with a median age of 46 years) at the Affiliated Hangzhou First People\'s Hospital, Medical College of Zhejiang University from December 2016 to December 2017. The written informed consent was signed by all patients. The experiments were conducted following the ethical standards and were approved by the Affiliated Hangzhou First People\'s Hospital, Medical College of Zhejiang University, approval number: AHFPH20161221.

Human normal oral cell line HGF‐1 and OSCC cell lines (YD‐38, MK‐1) were obtained from the American Type Culture Collection (ATCC) and Cell Bank (Shanghai, China). The cells were grown in RPMI‐1640 medium containing 10% heat‐inactivated fetal bovine serum (Gibco) and 1% penicillin‐streptomycin (Gibco) at 37°C with 5% CO~2~.

2.2. Cell transfection {#cam42808-sec-0008}
----------------------

For cell transfection, YD‐38 cells (3 × 10^4^/mL) were transfected with negative control (NC) small interfering (si) RNAs, *UCA1* siRNA (si‐UCA1, Ribobio), *MYO6* siRNA (si‐MYO6, Ribobio), or co‐transfected with si‐UCA1/si‐MYO6 and miR‐143‐3p inhibitor, or miR‐NC inhibitor (GenePharma). MK‐1 cells (3 × 10^4^/mL) were transfected with a blank pcDNA3.1 vector (Invitrogen), a pcDNA3.1 containing *UCA1* expression plasmid (pc‐UCA1) or *MYO6* plasmid (*MYO6*), or co‐transfected with pc‐UCA1/MYO6 and miR‐143‐3p mimics, or miR‐NC mimics (GenePharma) using Lipofectamine 2000 (Invitrogen). The final concentration of vectors and miRNAs was 100 nmol/L. After transfection for 48 hours, the cells were preserved for the subsequent assays.

2.3. Reverse transcription‐quantitative polymerase chain reaction (RT‐qPCR) {#cam42808-sec-0009}
---------------------------------------------------------------------------

Total RNA was extracted from OSCC tissues and cells by RNAiso Plus (Takara). To determine the levels of lncRNA, miRNA, and mRNA, the cDNA was obtained by RNA using RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific). The reaction was performed on ABI PRISM 7900HT system (Applied Biosystems) with SYBR Premix Ex Taq (Takara). The levels of *UCA1*/mRNA and miR‐143‐3p were normalized to *GAPDH* and *U6*, respectively. The primers used are listed in Table [1](#cam42808-tbl-0001){ref-type="table"} and the relative expressions were calculated by the 2^−ΔΔCt^ method.[23](#cam42808-bib-0023){ref-type="ref"}

###### 

Primers and sequences of qRT‐PCR

  Gene                 sequence (5′‐3′)
  -------------------- ------------------------
  *UCA1*‐Forward       TGACAACAGATAACCACCT
  *UCA1*‐Reverse       TCCGTATAGAAGACCACCTA
  miR‐143‐3p‐Forward   GGGGTGAGATGAAGCACTG
  miR‐143‐3p‐Reverse   CAGTGCGTGTCGTGGAGT
  *MYO6*‐Forward       CAGAGCAACGTGCTCCAAAGTC
  *MYO6*‐Reverse       GAAGCGTTGCTG TCGGTTCA
  MMP‐2‐Forward        TGATTCTGGTCGCTCAGATG
  MMP‐2‐Reverse        CTTGTTTCCCAGGAAGGTGA
  MMP‐9‐Forward        AGGACCATGGGGATCCTTAC
  MMP‐9‐Reverse        AACACAAGGCTGCCCATTAC
  E‐cadherin‐Forward   TAACCGATCAGAATGAC
  E‐cadherin‐Reverse   TTTGTCAGGGAGCTCAGGAT
  N‐cadherin‐Forward   CAACTTGCCAGAAAACTCCAGG
  N‐cadherin‐Reverse   ATGAAACCGGGCTATCTGCTC
  U6‐Forward           CTCGCTTCGGCAGCACATA
  U6‐Reverse           AACGATTCACGAATTTGCGT
  GAPDH‐Forward        CACCATTGGCAATGAGCGGTTC
  GAPDH‐Reverse        AGGTCTTTGCGGATGTCCACGT

John Wiley & Sons, Ltd

2.4. Differential gene expression analyses {#cam42808-sec-0010}
------------------------------------------

The <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE54672> dataset including one primary tumor tissue and one metastasis tissue was downloaded from the GEO. The differentially expressed genes (DEGs) were identified by interactive online tool GEO2R, with *P* \< .05 and log fold‐change (FC) \>2 served as the cutoff criteria. Venny 2.1 was used to identify the overlapping DEGs, which were upregulated in the <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE54672>, TargetScan7.2 datasets, and miRanda datasets.

2.5. Dual‐luciferase reporter assay {#cam42808-sec-0011}
-----------------------------------

The binding site between *UCA1* and miR‐143‐3p was determined by starbase v3.0 and that between *MYO6* and miR‐143‐3p was predicted by TargetScan7.2. The *UCA1* and *MYO6* wt/mut 3′‐UTR were, respectively, inserted into pmirGLO plasmid (Promega). Then, the vectors (2 µg/mL) were co‐transfected with miR‐NC or miR‐143‐3p mimics (50 nmol/L) into the cells using Lipofectamine 2000 reagent (Invitrogen). Luciferase activity was measured by the Dual‐Glo Luciferase assay (Promega).

2.6. Cell counting kit‐8 (CCK‐8) assay {#cam42808-sec-0012}
--------------------------------------

Cell growth was detected using CCK‐8 (Dojindo). Briefly, YD‐38 and MK‐1 cells (5 × 10^3^/well) were incubated for 24 or 48 hours. Then, CCK‐8 solution was added and incubated for another 4 hours. The optical density (OD) was measured at 490 nm using a microplate reader (Detie Laboratory Equipment Companya).

2.7. Wound healing assays and Transwell invasion assay {#cam42808-sec-0013}
------------------------------------------------------

The transfected cells (1 × 10^5^/well) were cultured in 6‐well plates until the cell confluence reached over 90%, and then a scratch was created using a 10‐μL pipette tip. The wound closures were observed and photographed at 0 and 24 hours after scratching under a microscope (Olympus). The wound closure was measured by ImageJ (v1.42, NIH).

To detect the invasive ability of OSCC cells, transwell chamber was treated with Matrigel (BD Biosciences). Next, the transfected cells (1 × 10^5^ cells/well) were seeded into the upper chamber containing serum‐free medium, while 600‐μL medium was added into the lower chamber. After incubation for 24 hours, the invaded cells were fixed, stained, and counted under a microscope (Olympus).

2.8. Western blot {#cam42808-sec-0014}
-----------------

The protein in tissues and cells was isolated in RIPA lysis buffer (Beyotime) and the concentration of protein was measured using BCA Kit (Beyotime). An equal amount of proteins were separated on 10% SDS‐PAGE (40 µg protein/lane) and then were transferred onto PVDF membranes (Millipore), which were incubated in 5% nonfat milk for 1 hour at room temperature. The membranes were subsequently incubated at 4°C overnight with primary antibodies including anti‐MYO6 (1:1000, ab230478, Abcam), anti‐MMP‐2 (1:1000, ab37150, Abcam), anti‐MMP‐9 (1:1000, ab38898, Abcam), anti‐GAPDH (1:1000, ab8245, Abcam), anti‐E‐cadherin (1:1000, \#3195, Cell Signaling Technology), and anti‐N‐cadherin (1:1000, \#13116, Cell Signaling Technology). Next, they were incubated with the HRP‐conjugated goat anti‐rabbit IgG (1:10 000, ab6721, Abcam) for 1 hour at room temperature. The bands were detected by enhanced chemiluminescence detection kit (Thermo scientific), and the intensity was quantified using ImageJ software v1.42 (NIH). The GAPDH served as a loading control.

2.9. Immunohistochemistry {#cam42808-sec-0015}
-------------------------

After immersing the sections in citrate (pH = 6.0) and antigen retrieval buffers, the paraffin‐embedded sections were treated with 3% H~2~O~2~ and incubated with 10% goat serum. After that, the sections were washed with Tris‐buffered saline Tween‐20 (TBST) and then incubated with rabbit polyclonal anti‐MYO6 (1:100, ab230478, Abcam) at 4°C overnight. Next, the sections were incubated with HRP‐conjugated goat anti‐rabbit IgG. The signal was detected by DAB Substrate kit following the manufacture\'s instruction and the images were observed under a microscope (Olympus).

2.10. Xenograft animal model {#cam42808-sec-0016}
----------------------------

Male nude mice (aged 4‐6 weeks old; weighting 20‐24 g) were purchased from Slac Laboratory Animal Center (Shanghai, China) and housed in an SPF‐grade barrier environment at the Affiliated Hangzhou First People\'s Hospital, Medical College of Zhejiang University, approval number: AHFPH20171230. The animal protocol was approved by the Institutional Animal Care and Use Committee of the Affiliated Hangzhou First People\'s Hospital, Medical College of Zhejiang University. The transfected cells (5 × 10^7^/mL, 0.1 mL) were subcutaneously injected into the nude mice (n = 5 per group). Four weeks later, the mice were sacrificed and the tumor tissues were photographed, weighed, and collected for immunohistochemistry and Western blot.

2.11. Statistical analysis {#cam42808-sec-0017}
--------------------------

GraphPad Prism version 5.0 (GraphPad Software) was used to analyze the data, which were shown as the mean ± standard deviation (SD). Student\'s *t* tests were used to examine differences between the two groups, whereas differences between three or more groups were analyzed by one‐way ANOVA. The significance of correlations among *UCA1*, miR‐143‐3p, and *MYO6* levels was assessed by the Pearson correlation coefficient. A *P* \< .05 was considered as statistically significant. All experiments were repeated at least in triplicate.

3. RESULTS {#cam42808-sec-0018}
==========

3.1. *UCA1* is upregulated in OSCC and sponges miR‐143‐3p {#cam42808-sec-0019}
---------------------------------------------------------

To explore whether *UCA1* is abnormal in OSCC, we measured the level of *UCA1* in 56 OSCC tissues and matched normal ones. The level of *UCA1* was increased more in the tumor tissues than that in normal tissues (*P* \< .001, Figure [1](#cam42808-fig-0001){ref-type="fig"}A); however, the level of miR‐143‐3p exhibited an opposite trend (*P* \< .001, Figure [1](#cam42808-fig-0001){ref-type="fig"}B), showing a notably negative correlation with *UCA1* expression (*P* \< .001, Figure [1](#cam42808-fig-0001){ref-type="fig"}C). Similarly, the *UCA1* showed a higher level in the two OSCC cell lines than that in human normal oral cells, while miR‐143‐3p had an opposite expression (*P* \< .01, Figure [1](#cam42808-fig-0001){ref-type="fig"}D,E).

![The level of lncRNA *UCA1* is increased and that of miR‐143‐3p is reduced in OSCC, and lncRNA *UCA1* is a sponge of miR‐143‐3p. The levels of lncRNA *UCA1* (A) and miR‐143‐3p (B) were determined in OSCC tissues and adjacent noncancerous tissues by qRT‐PCR. C, Scatter diagram revealed a negative correlation between *UCA1* and miR‐143‐3p in 56 pairs of OSCC tissues by RT‐qPCR. The lncRNA *UCA1* (D) and miR‐143‐3p (E) were detected in OSCC cell lines and human normal oral cell line by RT‐qPCR.(F) The miR‐122 binding position on *UCA1* was predicted by starbase v3.0. G and H, Dual‐luciferase reporter assay of OSCC cells co‐transfected with wt/mut *UCA1* sequence and miR‐143‐3p mimics or the miR‐NC. ^\*\*^ *P* \< .01](CAM4-9-3115-g001){#cam42808-fig-0001}

To further assess the clinical significance of *UCA1* expression in OSCC, the OSCC patients were assigned into high (n = 25) and low (n = 31) expression groups according to the median level of expression. As shown in Table [2](#cam42808-tbl-0002){ref-type="table"}, high *UCA1* expression was remarkably correlated with lymphatic metastasis and recurrence. We also evaluated the clinical significance of miR‐143‐3p in OSCC. We found that low level of miR‐143‐3p was significantly related to lymphatic metastasis and recurrence (Table [3](#cam42808-tbl-0003){ref-type="table"}).

###### 

The relationship between *UCA1* expression and clinical characteristics of oral squamous cell carcinoma

+----------------------+----------+-------------+-------------+-------+------+
| Characteristics      | Patients | *UCA1*      | *χ^2^*      | *P*   |      |
|                      |          |             |             |       |      |
|                      | (n = 56) |             |             |       |      |
+======================+==========+=============+=============+=======+======+
| Age                  |          |             |             |       |      |
+----------------------+----------+-------------+-------------+-------+------+
| ≤60                  | 30       | 13 (43.33%) | 17 (56.67%) | 0.045 | .832 |
+----------------------+----------+-------------+-------------+-------+------+
| \>60                 | 26       | 12 (46.15%) | 14 (53.85%) |       |      |
+----------------------+----------+-------------+-------------+-------+------+
| Sex                  |          |             |             |       |      |
+----------------------+----------+-------------+-------------+-------+------+
| Male                 | 32       | 14 (43.75%) | 18 (56.25%) | 0.024 | .877 |
+----------------------+----------+-------------+-------------+-------+------+
| Female               | 24       | 11 (45.83%) | 13 (54.17%) |       |      |
+----------------------+----------+-------------+-------------+-------+------+
| Lymphatic metastasis |          |             |             |       |      |
+----------------------+----------+-------------+-------------+-------+------+
| Present              | 23       | 14 (60.87%) | 9 (39.13%)  | 4.159 | .041 |
+----------------------+----------+-------------+-------------+-------+------+
| Absent               | 33       | 11 (33.33%) | 22 (66.67%) |       |      |
+----------------------+----------+-------------+-------------+-------+------+
| Recurrence           |          |             |             |       |      |
+----------------------+----------+-------------+-------------+-------+------+
| Present              | 18       | 12 (66.67%) | 6 (33.33%)  | 5.206 | .023 |
+----------------------+----------+-------------+-------------+-------+------+
| Absent               | 38       | 13 (34.21%) | 25 (65.79%) |       |      |
+----------------------+----------+-------------+-------------+-------+------+
| Absent               | 38       | 24 (63.16%) | 14 (36.84%) |       |      |
+----------------------+----------+-------------+-------------+-------+------+

John Wiley & Sons, Ltd

###### 

The relationship between miR‐143‐3p expression and clinical characteristics of oral squamous cell carcinoma

+----------------------+----------+-------------+-------------+-------+------+
| Characteristics      | Patients | miR‐143‐3p  | *χ^2^*      | *P*   |      |
|                      |          |             |             |       |      |
|                      | (n = 56) |             |             |       |      |
+======================+==========+=============+=============+=======+======+
| Age                  |          |             |             |       |      |
+----------------------+----------+-------------+-------------+-------+------+
| ≤60                  | 30       | 15 (50.00%) | 15 (50.00%) | 0.331 | .565 |
+----------------------+----------+-------------+-------------+-------+------+
| \>60                 | 26       | 15 (57.69%) | 11 (42.31%) |       |      |
+----------------------+----------+-------------+-------------+-------+------+
| Sex                  |          |             |             |       |      |
+----------------------+----------+-------------+-------------+-------+------+
| Male                 | 32       | 17 (53.13%) | 15 (46.87%) | 0.006 | .938 |
+----------------------+----------+-------------+-------------+-------+------+
| Female               | 24       | 13 (54.17%) | 11 (45.83%) |       |      |
+----------------------+----------+-------------+-------------+-------+------+
| Lymphatic metastasis |          |             |             |       |      |
+----------------------+----------+-------------+-------------+-------+------+
| Present              | 23       | 8 (34.78%)  | 15 (65.22%) | 5.540 | .019 |
+----------------------+----------+-------------+-------------+-------+------+
| Absent               | 33       | 22 (66.67%) | 11 (33.33%) |       |      |
+----------------------+----------+-------------+-------------+-------+------+
| Recurrence           |          |             |             |       |      |
+----------------------+----------+-------------+-------------+-------+------+
| Present              | 18       | 6 (33.33%)  | 12 (66.67%) | 4.368 | .037 |
+----------------------+----------+-------------+-------------+-------+------+
| Absent               | 38       | 24 (63.16%) | 14 (36.84%) |       |      |
+----------------------+----------+-------------+-------------+-------+------+
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*UCA1* has been reported as ceRNAs to specific miRNAs in regulating tumor progression. Here, starbase v3.0 identified that *UCA1* had a complementary binding site with miR‐143‐3p (Figure [1](#cam42808-fig-0001){ref-type="fig"}F). Furthermore, the miR‐143‐3p mimics obviously suppressed the luciferase activity of the vector containing *UCA1*‐WT (*P* \< .01); however, it had no effect on that of the vector with *UCA1*‐Mut in YD‐38 and MK‐1 cells (Figure [1](#cam42808-fig-0001){ref-type="fig"}G,H).

3.2. MiR‐143‐3p reverses the *UCA1*‐induced OSCC cell proliferation, migration, and invasion {#cam42808-sec-0020}
--------------------------------------------------------------------------------------------

To validate our speculation that *UCA1* promotes proliferation, migration, and invasion of OSCC cells by acting as a sponge of miR‐143‐3p, the *UCA1* and miR‐143‐3p expressions in transfected cells were determined. The *UCA1* expression was notably decreased by si‐UCA1 but were increased in the cells transfected with pc‐UCA1 (*P* \< .01); meanwhile, the miR‐143‐3p mimics or inhibitors had no significant effects on the *UCA1* expression (Figure [2](#cam42808-fig-0002){ref-type="fig"}A,B). In addition, the levels of miR‐143‐3p in si‐UCA1 group and mimic group were upregulated but could be inhibited by pc‐UCA1 and inhibitors (*P* \< .01, Figure [2](#cam42808-fig-0002){ref-type="fig"}C,D). The CCK8 assay results showed that compared with the controls, knocking down *UCA1* in YD‐38 cells significantly suppressed the cell viability, which, however, was rescued by the miR‐143‐3p inhibitors (*P* \< .05, Figure [2](#cam42808-fig-0002){ref-type="fig"}E). In MK‐1 cells, the overexpressed *UCA1* greatly promoted cell proliferation, and miR‐143‐3p mimics attenuated the effect of *UCA1* (*P* \< .05, Figure [2](#cam42808-fig-0002){ref-type="fig"}F).

![LncRNA *UCA1* promotes OSCC cell proliferation, migration, and invasion by inhibiting miR‐143‐3p. A and B, The lncRNA *UCA1* expression in YD‐38 and MK‐1 cells 48 h after transfection was determined by RT‐qPCR. C and D, The miR‐143‐3p expressions in YD‐38 and MK‐1 cells 48 h after the transfection were determined by RT‐qPCR. E and F, CCK‐8 assays of YD‐38 and MK‐1 cell proliferation at 24 h and 48 h. G and H, Representative images of cell migration in each group of YD‐38 and MK‐1 cells at 0 h and 24 h. I and J, Representative images of cell invasion in each group of YD‐38 and MK‐1 cells at 24 h. K and L, Migration distance in each group of YD‐38 and MK‐1 cells. M and N, The number of invasive cells in each group of YD‐38 and MK‐1 cells. ^\*^ *P* \< .05, ^\*\*^ *P* \< .01](CAM4-9-3115-g002){#cam42808-fig-0002}

To further investigate the effect of *UCA1* on metastasis, wound healing and transwell assays were performed (Figure [2](#cam42808-fig-0002){ref-type="fig"}G‐J). The inhibition of *UCA1* by siRNA effectively suppressed cell migration and invasion, while overexpressed *UCA1* greatly accelerated the migration and invasion in comparison to those in control groups; however, these effects of *UCA1* were reversed by miR‐143‐3p (*P* \< .01, Figure [2](#cam42808-fig-0002){ref-type="fig"}K‐N).

3.3. *UCA1* positively regulates *MYO6* by sponging miR‐143‐3p {#cam42808-sec-0021}
--------------------------------------------------------------

The genes that were potentially regulated by miR‐143‐3p were determined. For the <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE54672> dataset, a total of 2232 upregulated DEGs were extracted, and 17 DEGs, including *MYO6*, had overlapping area in the three databases (Figure [3](#cam42808-fig-0003){ref-type="fig"}A). The targeted binding site between miR‐143‐3p and *MYO6* was predicted by TargetScan7.2 (Figure [3](#cam42808-fig-0003){ref-type="fig"}B), and luciferase reporter assays verified that miR‐143‐3p mimics markedly reduced the luciferase activity in the *MYO6*‐wt group but it had no effect on the *MYO6*‐mut group in YD‐38 and MK‐1 cells (Figure [3](#cam42808-fig-0003){ref-type="fig"}C,D). The protein and mRNA levels of *MYO6* were detected by Western blot and RT‐qPCR in transfected OSCC cells. The pc‐UCA1 or miR‐143‐3p inhibitors increased *MYO6*, which was significantly suppressed by si‐UCA1 or miR‐143‐3p mimics (*P* \< .01, Figure [4](#cam42808-fig-0004){ref-type="fig"}A‐F). The *MYO6* expression in co‐transfected cells exhibited no significant difference from that in the control group. Moreover, the RT‐qPCR and immunohistochemistry results showed that *MYO6* in the OSCC tissues was greatly elevated compared with that in normal tissues (*P* \< .01, Figure [4](#cam42808-fig-0004){ref-type="fig"}G‐I). We found that *MYO6* was negatively correlated with miR‐143‐3p but positively correlated with *UCA1* in 56 pairs of OSCC tissues by qRT‐PCR (*P* \< .001, Figure [4](#cam42808-fig-0004){ref-type="fig"}J,K).

![MiR‐143‐3p directly targets *MYO6* in OSCC cells. A, The <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE54672> dataset, miRDB website, and Targetscan website were used to predict the overlapped mRNA of miR‐143‐3p. B, The predicted miR‐143‐3p binding site in the *MYO6* using Targetscan7.2. C and D, Dual‐luciferase reporter assay of OSCC cells co‐transfected with wt/mut *MYO6* and miR‐143‐3p mimics or the miR‐NC. ^\*\*^ *P* \< .01](CAM4-9-3115-g003){#cam42808-fig-0003}

![*MYO6* is elevated in OSCC. A, Western blot of *MYO6* in each group of YD‐38 cells. B, The protein levels of the *MYO6* in YD‐38 cells. C, The mRNA expression of *MYO6* in each group of YD‐38 cells. D, Western blot of *MYO6* in each group of MK‐1 cells. E, The protein levels of the *MYO6* in MK‐1 cells. F, The mRNA expression of *MYO6* in each group of MK‐1 cells. G, The *MYO6* was detected in OSCC tissues and adjacent noncancerous tissues by qRT‐PCR. H, Representative immunohistochemical images of OSCC tumor sections for *MYO6* (scale bar = 100 μm). I, The staining intensity of *MYO6* by immunohistochemistry. J and K, Scatter diagram showed a positive correlation of *UCA1* and *MYO6* and a negative correlation of miR‐143‐3p and *MYO6* in 56 pairs of OSCC tissues by RT‐qPCR. ^\*^ *P* \< .05, ^\*\*^ *P* \< .01](CAM4-9-3115-g004){#cam42808-fig-0004}

3.4. *MYO6* promotes OSCC cell proliferation and metastasis in vitro {#cam42808-sec-0022}
--------------------------------------------------------------------

To confirm the effect of *MYO6* on the OSCC progression, *MYO6* expression in OSCC cells was determined at the protein and mRNA levels. The knockdown of *MYO6* in YD‐38 cells and overexpression of *MYO6* in MK‐1 cells were effective, and miR‐143‐3p reversed the expression tendency of *MYO6* (*P* \< .01, Figure [5](#cam42808-fig-0005){ref-type="fig"}A‐F).

![MiR‐143‐3p negatively regulates *MYO6* in OSCC cell lines. A, Western blot analysis of *MYO6* in each group of YD‐38 cells. B, The protein expression of the *MYO6* in YD‐38 cells. C, The mRNA expression of *MYO6* in each group of YD‐38 cells. D, Western blot analysis of *MYO6* in each group of MK‐1 cells. E, The protein expression of the *MYO6* in MK‐1 cells. F, The mRNA expression of *MYO6* in each group of MK‐1 cells. ^\*^ *P* \< .05, ^\*\*^ *P* \< .01](CAM4-9-3115-g005){#cam42808-fig-0005}

The CCK‐8 results showed that proliferation of YD‐38 cells was sharply inhibited by the knockdown of *MYO6* but significantly increased by miR‐143‐3p inhibitors (*P* \< .01, Figure [6](#cam42808-fig-0006){ref-type="fig"}A). Moreover, the MK‐1 cell growth was greatly improved by overexpressing *MYO6* but suppressed by miR‐143‐3p mimics (*P* \< .01, Figure [6](#cam42808-fig-0006){ref-type="fig"}B). Similarly, the inhibitory effect of miR‐143‐3p on cell migration and invasion was also rescued by *MYO6* (*P* \< .01, Figure [6](#cam42808-fig-0006){ref-type="fig"}C‐J).

![MiR‐143‐3p inhibits OSCC cell proliferation, migration, and invasion by inhibiting *MYO6*. A and B, CCK‐8 assays of YD‐38 and MK‐1 cell proliferation in each group at 24 and 48 h. C and D, Representative images of cell migration in each group of YD‐38 and MK‐1 cells at 0 and 24 h. E and F, Representative images of cell invasion in each group of YD‐38 and MK‐1 cells at 24 h. G and H, Migration distance in each group of YD‐38 and MK‐1 cells. I and J, The number of invasive cells in each group of YD‐38 and MK‐1 cells. ^\*^ *P* \< .05, ^\*\*^ *P* \< .01](CAM4-9-3115-g006){#cam42808-fig-0006}

3.5. *UCA1* facilitates tumor progression in vivo {#cam42808-sec-0023}
-------------------------------------------------

To further determine the role of *UCA1* in OSCC tumorigenesis in vivo, transfected cells were injected into the nude mice, and we found that *UCA1* silencing significantly suppressed tumor weight and size in xenograft mice; however, overexpressing *UCA1* noticeably accelerated tumor growth, and the effect of *UCA1* was attenuated by miR‐143‐3p (*P* \< .01, Figure [7](#cam42808-fig-0007){ref-type="fig"}A‐D). Additionally, the protein and mRNA expressions of *MYO6* were significantly reduced in the si‐UCA1 group but elevated in the pc‐UCA1 group, and miR‐143‐3p overturned these functions of *UCA1* (*P* \< .01, Figure [7](#cam42808-fig-0007){ref-type="fig"}E‐J). Moreover, immunohistochemical staining for *MYO6* was also consistent with the protein and mRNA expressions of *MYO6* (*P* \< .01, Figure [8](#cam42808-fig-0008){ref-type="fig"}A‐D).

![LncRNA *UCA1* promotes tumor growth in a xenograft mouse model of OSCC. A‐D, Xenograft tumor was photographed and tumor weight was measured in each group of YD‐38 and MK‐1 cells. E, Western blot analysis of *MYO6* in each group of YD‐38 cells. F, The protein expression of the *MYO6* in YD‐38 cells. G, The mRNA expression of *MYO6* in each group of YD‐38 cells. H, Western blot analysis of *MYO6* in each group of MK‐1 cells. I, The protein expression of the *MYO6* in MK‐1 cells. J, The mRNA expression of *MYO6* in each group of MK‐1 cells. ^\*^ *P* \< .05, ^\*\*^ *P* \< .01](CAM4-9-3115-g007){#cam42808-fig-0007}

![LncRNA *UCA1* upregulates *MYO6* in a xenograft mouse model of OSCC. A, Representative immunohistochemical images for *MYO6* of tumor sections from xenograft mice injected with YD‐38 cells (scale bar = 100 μm). B, The staining intensity of *MYO6* by immunohistochemistry. C, Representative immunohistochemical images for *MYO6* of tumor sections from xenograft mice injected with MK‐1 cells (scale bar = 100 μm). D, The staining intensity of *MYO6* by immunohistochemistry. ^\*^ *P* \< .05, ^\*\*^ *P* \< .01](CAM4-9-3115-g008){#cam42808-fig-0008}

To understand the effect of *UCA1* on the OSCC metastasis, we measured the epithelial‐mesenchymal transition (EMT) markers and two matrix metalloproteinases (MMPs) of the tumor tissues in the mice. When *UCA1* was suppressed, the expression of E‐cadherin (epithelial marker) was notably increased in the mRNA and protein levels, while the N‐cadherin (mesenchymal marker), MMP‐2, and MMP‐9 were downregulated (*P* \< .01, Figure [9](#cam42808-fig-0009){ref-type="fig"}A‐C). However, when *UCA1* was upregulated, the expression patterns of these molecules were the opposite (*P* \< .01, Figure [9](#cam42808-fig-0009){ref-type="fig"}D‐F).

![LncRNA *UCA1* promotes EMT makers in a xenograft mouse model of OSCC. A, Western blot of EMT makers in each group of tumors from xenograft mice injected with YD‐38 cells. B and C, The protein and mRNA levels of the EMT makers in tumors from xenograft mice injected with YD‐38 cells. D, Western blot of EMT makers in each group of tumors from xenograft mice injected with MK‐1 cells. E and F, The protein and mRNA expression of the EMT makers in tumors from xenograft mice injected with MK‐1 cells. ^\*^ *P* \< .05, ^\*\*^ *P* \< .01](CAM4-9-3115-g009){#cam42808-fig-0009}

4. DISCUSSION {#cam42808-sec-0024}
=============

Evidence indicated that lncRNAs are vital regulators in physiological process of cancers.[24](#cam42808-bib-0024){ref-type="ref"}, [25](#cam42808-bib-0025){ref-type="ref"} However, there are still limited studies performed on lncRNAs in OSCC. Therefore, it is urgent to determine the molecular mechanism of OSCC progression and discover effective therapy targets based on lncRNA.

Dysregulation of lncRNAs, including *HOXA11‐AS*, *LEF1‐AS1*, and *TUG1*, is involved in OSCC progression.[26](#cam42808-bib-0026){ref-type="ref"}, [27](#cam42808-bib-0027){ref-type="ref"}, [28](#cam42808-bib-0028){ref-type="ref"} Moreover, lncRNA *ADAMTS9‐AS2* can promote tongue squamous cell carcinoma proliferation, migration, and EMT.[29](#cam42808-bib-0029){ref-type="ref"} However, the roles of lncRNAs in OSCC progression have not been clearly elucidated. Herein, we investigated the potential effect of the lncRNA *UCA1* on OSCC, and found that *UCA1* promotes OSCC cell proliferation, migration, and invasion in vitro and in vivo, suggesting that it could be a potential therapeutic target for treating OSCC.

Studies suggest that *UCA1* serves as an oncogene in various human cancers, for instance, it promotes the growth of adrenocortical cancer cells, while silencing *UCA1* can inhibit hemangioma cell growth, migration, and invasion.[30](#cam42808-bib-0030){ref-type="ref"}, [31](#cam42808-bib-0031){ref-type="ref"} *UCA1* also plays an oncogenic role in nasopharyngeal carcinoma,[32](#cam42808-bib-0032){ref-type="ref"} osteosarcoma,[33](#cam42808-bib-0033){ref-type="ref"} colon,[34](#cam42808-bib-0034){ref-type="ref"} and pancreatic cancer.[35](#cam42808-bib-0035){ref-type="ref"} Additionally, *UCA1* can act as a potential molecular marker for metastasis and prognosis in multiple cancers.[36](#cam42808-bib-0036){ref-type="ref"} In our study, *UCA1* increased both in OSCC tissues and cells and promoted OSCC progression in vitro and in vivo.

Moreover, high expression of *UCA1* was associated with lymphatic metastasis and recurrence of OSCC patients. Previous studies showed that EMT plays a pivotal role in tissue metastasis.[37](#cam42808-bib-0037){ref-type="ref"} LncRNAs are involved in EMT, for instance, the knockdown of lncRNA *SNHG7* suppresses EMT in prostate cancer,[38](#cam42808-bib-0038){ref-type="ref"} and downregulated *HAGLR* inhibits EMT and metastatic potential in esophageal cancer.[39](#cam42808-bib-0039){ref-type="ref"} As a result, *UCA1* may be conducive to OSCC metastasis via facilitating the EMT process. To further confirm our speculation, we detected the EMT markers (E‐cadherin and N‐cadherin) and MMPs in tumors from xenograft mice, and discovered that E‐cadherin was notably increased but N‐cadherin, MMP‐2, and MMP‐9 were greatly suppressed by si‐UCA1, indicating that the overexpression of *UCA1* can enhance proliferation and EMT to cause an aggressive clinical outcome to OSCC patients.

LncRNAs can act as molecular sponges to miRNAs.[40](#cam42808-bib-0040){ref-type="ref"} *UCA1* is reported to regulate cancer progression by acting as a sponge for miR‐582‐5p,[41](#cam42808-bib-0041){ref-type="ref"} miR‐204,[42](#cam42808-bib-0042){ref-type="ref"} miR‐495‐3p,[43](#cam42808-bib-0043){ref-type="ref"} and other miRNAs. Therefore, we identified some potential target miRNAs of *UCA1* in OSCC using bioinformatics tools, and miR‐143‐3p was confirmed as a potential target for *UCA1*. Previous reports have revealed that miR‐143‐3p inhibits colorectal cancer metastases by targeting *ITGA6* and *ASAP3*.[44](#cam42808-bib-0044){ref-type="ref"} In addition, miR‐143‐3p suppresses the growth and invasiveness of melanoma cells by targeting cyclooxygenase‐2.[45](#cam42808-bib-0045){ref-type="ref"} Furthermore, miR‐143‐3p can be targeted by other lncRNAs, including *ADAMTS9‐AS2*,[46](#cam42808-bib-0046){ref-type="ref"} *OIP5‐AS1*,[47](#cam42808-bib-0047){ref-type="ref"} and *OECC*,[48](#cam42808-bib-0048){ref-type="ref"} to inhibit tumor cell invasion and migration. Herein, we found that miR‐143‐3p mimics exerted an inhibitory effect on the OSCC cell growth and metastasis and was related to lymphatic metastasis and recurrence of patients with OSCC.

We discovered that miR‐143‐3p suppressed OSCC progression via targeting *MYO6*. The data revealed that *MYO6* exhibited a tumor‐promoting property in various cancers, including prostate,[19](#cam42808-bib-0019){ref-type="ref"} gastric,[21](#cam42808-bib-0021){ref-type="ref"} breast,[49](#cam42808-bib-0049){ref-type="ref"} and lung cancer.[50](#cam42808-bib-0050){ref-type="ref"} Moreover, consistent with previous studies, we observed that *MYO6* is a downstream target for miR‐143‐3p,[51](#cam42808-bib-0051){ref-type="ref"} and that *MYO6* can also be regulated by lncRNA such as *SOX21‐AS1*.[52](#cam42808-bib-0052){ref-type="ref"} We also found that *MYO6* was elevated in OSCC tissues and cells, and increased *MYO6* reversed the inhibitory effects of miR‐143‐3p on OSCC cells, suggesting that miR‐143‐3p attenuated OSCC cell proliferation, migration, and invasion by suppressing *MYO6*. However, this study is still incomplete, and we still need to further verify the effect of *MYO6* on EMT of OSCC cells.

5. CONCLUSION {#cam42808-sec-0025}
=============

In conclusion, our study indicates that *UCA1* expression was significantly elevated in OSCC tissues and cells and was correlated with the metastasis and recurrence of OSCC patients. Moreover, the overexpression of *UCA1* markedly promoted OSCC progression in vitro and in vivo by upregulating *MYO6* expression as a sponge of miR‐143‐3p.
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